News
-
![[DI+Pharmaceutical Information] Corestemchemon, a Leading Pharmaceutical Company with the Innovative Drug for Stem Cells](/upload/press/202312/thumb/1702962598_m0175481_20231219140958.png)
[DI+Pharmaceutical Information] Corestemchemon, a Leading Pharmaceutical Company with the Innovative Drug for Stem Cells
2023.12.19
-
CorestemChemon Ground Breaking Advanced Biopharmaceutical Center... "Aims to Operate the Center in 2024"
2023.12.19
-
Corestemchemon Released the Data of Sales of NeuroNata-R in Conference of Amyotrophic Lateral Sclerosis in Asia-Pacific Region
2023.12.19
-
Corestemchemon Opened Its Branch in Washington, D.C. -- Realizing Entering the Global Market
2023.12.19
-
Corestemchemon "Neuronata-R, a Drug Treating Amyotrophic Lateral Sclerosis, Extended Living Period by 5.6 Years."
2023.12.19
-
Corestemchemon Has Done Administering Neuronata-R to Patients in Phase 1 to Extend the Validity of Its Drug.
2023.12.19
-
Pay Attention to Neuronata-R of Corestemchemon -- Mesenchymal Stem Cell Treats Amyotrophic Lateral Sclerosis (ALS)
2023.12.19
-
Relyvrio, Tofersen, and More Drugs for ALS? Corestemchemon is also drawing attention.
2023.12.19
-
Corestem Shares Protocol for Long-term NeuroNata-R Trial
2023.12.14